GlobeNewsWire
05 Jan 2026, 21:01 UTC · 36w ago
Verdict
Headline takes no side. We score GLPG −0.40 across four claims — moderately bearish.
−0.40moderately bearish
More negative than 76% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Galapagos will wind down its cell therapy activities and close sites in the Netherlands, Switzerland, the U.S., and China, impacting approximately 365 employees.
So whatExiting a major therapeutic platform and incurring significant restructuring costs reduces the company's operational footprint and near-term revenue potential, weighing on valuation.
More negative than 96% of claims this week
Galapagos holds approximately €3.0 billion in cash and cash equivalents, and financial investments as of December 31, 2025.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 91% of claims this week
Galapagos will evaluate all strategic alternatives for its TYK2 program GLPG3667, including resuming a partnering process for further development in dermatomyositis and other auto-immune indications.
More positive than 77% of claims this week
Following the cell therapy wind-down, the remaining Galapagos organization will seek to reposition for long-term growth through transformational business development.
More positive than 54% of claims this week
Which stocks this story touches
More negative than 76% of ticker scores this week
The company is winding down its cell therapy activities, resulting in the closure of multiple global sites and the loss of approximately 365 jobs.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Benzinga
3h ago
−14.5%
Price agrees with the score
$27.98 vs $32.74 close before publication (Jan 5) · not market-adjusted
GLPG chart →
